ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share

ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share

Geneva, Switzerland, 19 November 2015
 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that the independent life science research company valuationLAB AG has issued an updated research report on Addex Therapeutics. The research report estimates a current “risk-adjusted NPV (net present value) of CHF 5.2 per share” (ADXN closing price 18 November 2015: CHF3.00).

ValuationLAB’s current valuation is based only on Addex clinical stage programs, dipraglurant for Parkinson’s disease levodopa induced dyskinesia (PD-LID) and ADX71149 which is partnered with Janssen Pharmaceuticals Inc. The valuationLAB report also provides detailed analysis of significant upside in the current valuation should Addex successfully execute on its strategy to advance dipraglurant for PD-LID and dystonia, and ADX71441 for Charcot-Marie-Tooth type 1A neuropathy (CMT1A).

Key upcoming milestones include:


  • reporting data from the ongoing dipraglurant PET receptor occupancy study which will provide important data for the selection of thee dose to enter the next study, a Phase III pivotal trial;
  • news from the FDA on our application for orphan drug designation for dipraglurant in Parkinson’s disease levodopa-induced- dyskinesia;
  • data in cocaine addiction from our US National Institute for Drug Abuse collaboration
  • data in CMT1A from our CMTA collaboration
  • data in neurodegenerative diseases from our collaboration with the University of Lausanne and the Ecole Polytechnic Federal Lausanne

“We are impressed with the progress Addex is making to deliver on its new strategy to unlock the hidden value of its portfolio.” commented Bob Pooler, CEO of valuationLAB. “Since our last report Addex has over delivered on its milestones including entering a collaboration with Pierre Fabre and announcing positive data in alcohol use disorder under its NIAAA collaboration.” 

“We are pleased with the progress being made in the execution of our strategy including, the dipraglurant PET receptor occupancy study which is on track to report data by year end,” commented Tim Dyer, CEO of Addex. We believe this analyst report provides useful guidance to the investment community on the Addex investment case as we execute on our strategy to unlock the value of the Addex portfolio for our shareholders.”

The full analyst research report is available on and on Addex website at under Investors/downloads/analyst reports (direct link)

About valuationLAB and their research report
valuationLAB AG is an independent life science research boutique with no securities or banking services. The company does not hold any positions in the securities mentioned in its reports. Its financial analyses are based on the Directives on the Independence of Financial Research issued by the Swiss Bankers Association in January 2008. valuationLAB’s aim is to translate complicated scientific/clinical data into easy-to-understand financial forecasts and valuations for investors. Valuations are based on tailor-made, detailed, bottom-up research from publicly available sources. The Addex Valuation Report has been commissioned by Addex Therapeutics Ltd. and prepared and issued by valuationLAB AG. The analyst views and expectations were made independently and as such do not necessarily reflect those of Addex.

About Addex Therapeutics
Addex Therapeutics ( is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is currently being evaluated in a PET receptor occupancy study as part of its preparation to enter a Phase III pivotal trial for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase I and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGluR4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGluR2NAM for treatment resistant depression and cognitive deficits; mGluR7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

Tim Dyer
Chief Executive Officer
Addex Therapeutics
Telephone: +41 22 884 15 61
Email: PR(at)

Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.